Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Alexion Pharmaceuticals, Inc. (ALXN - Analyst Report) recently announced preliminary results from a single-arm phase II study (n=47) on Soliris, being developed to prevent acute antibody-mediated rejection (AMR) in sensitized deceased-donor kidney transplant recipients.

Alexion presented results from this study at the 2013 annual congress of the European Society for Organ Transplantation.

Results from the study revealed that post-transplantation treatment failure occurred in 10.6% patients. This included a 6.4% rate of AMR1 in these kidney transplant recipients in comparison to an expected 30% rate of AMR2. Alexion intends to continue enrolling patients for the study. Alexion mentioned in its press release that currently there are no approved treatments for the prevention of acute AMR. We note that Soliris is not yet approved for the prevention of AMR indication in any other country.

We also note that Soliris is approved in more than 40 countries including the U.S. and the EU for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The drug is also available in the U.S., EU and other countries for the treatment of atypical hemolytic uremic syndrome (aHUS). Soliris enjoys orphan drug designation for both these indications in the U.S. and the EU.

Alexion’s revenues jumped 35% to approximately $370.1 million in the second quarter of 2013 driven by strong Soliris sales. Approval of the drug for additional indications will boost sales of the drug further.

Alexion currently carries a Zacks Rank #3 (Hold). Meanwhile, stocks such as Actelion Ltd. (ALIOF), Biogen Idec Inc. (BIIB - Analyst Report) and Gilead Sciences Inc. (GILD - Analyst Report), carrying a Zacks Rank #1 (Strong Buy), currently look more attractive.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GENERAL FINA GFN 8.20 +5.67%
QIHOO 360 TE QIHU 91.57 +4.38%
VIPSHOP HOLD VIPS 140.01 +3.49%
INVESTMENT T ITG 19.16 +3.34%
VERTEX ENERG VTNR 7.38 +3.07%